Search

Background: Coronavirus contribute to respiratory illness, including severe disease. COVID-19 infection is associated with multiple acute complications including post viral fatigue syndrome. Healthcare workers have a higher rate of exposure to this virus which crippled the healthcare system. Patients acutely infected with SARS-CoV-2, demonstrate elevated inammatory markers. Hence in this study we sought to establish whether patients of SARS-CoV-2 infection remained fatigued post recovery and whether there was a relationship between severe fatigue and inammatory markers. 390 COVID-19 Materials And Methods: positive healthcare workers were studied at Assam Medical College and Hospital from July 2021 to June 2022. Assessment of fatigue was done using the Prole of Fatigue Related Symptoms (PFRS) score. In our study, maximum belong to age group 18-30 ye Results: ars of age (45.64%). Out of 390 cases, 211 (54.10%) were female. 180 (46.2%) had elevated LDH, 209 (53.6%) had elevated CRP. 18 (4.6%) had an SPO2 of < 90% in room air, post viral fatigue syndrome was present in 201 (51.54%) out of which 38(9.75%) had extreme fatigue symptoms, 163(41.79%) had moderate fatigue symptoms. The association between the association between post viral fatigue syndrome and inammatory markers (LDH and CRP) was signicant (p < 0.001). There was a signicant association between inamma Conclusion: tory markers (LDH and CRP) with Post Viral Fatigue Syndrome in COVID-19. . Hence, proper assessment after ruling out other co-existent diseases and using the Prole of Fatigue Related Symptoms (PFRS) score, may help in identifying cases of Post Viral Fatigue Syndrome

Background Japanese encephalitis virus (JEV) remains the major etiology of encephalitis throughout Asia. In India, the state of Assam alone contributes more than one-third of the national burden of JE. Between 2011 and 2014, a single dose of JE vaccine SA 14-14-2 (LAJEV) was administered among adults aged 15–65 years residing in Sivasagar and Dibrugarh districts of Assam, India. We monitored the trend of JE incidence between 2009 and 2018 using JE surveillance data, estimated the long-term effectiveness of the single dose of LAJEV and estimated the coverage of JE vaccine in two districts. Methods We compared the JE vaccination status of laboratory-confirmed hospitalized JE patients (case) and age, sex and locality matched healthy individuals (controls) to estimate the effectiveness of single dose of JE vaccine. We used surveillance data for 2009–2018 to calculate the incidence of JE among adults. We conducted a community-based survey to estimate the coverage of JE vaccine in the two districts. Results A total of 452 laboratory-confirmed JE case-patients and 904 matched healthy controls were enrolled in the study between 2012 and 2018. The effectiveness of a single dose of JE vaccine over the 7-year period was 77.0 (95% CI: 67.0–83.0). Vaccine effectiveness decreased from 91% (95% CI: 73.0–97.0) in first year of vaccination to 71% (95% CI: 21.0–90.0) at six years post-vaccination. The incidence of adults JE cases declined from 10.5 per 100,000 in the pre-vaccination period to 5.7 per 100,000 in the years following vaccination. The coverage of vaccine among adults in two districts was 40.1% (36.8–43.5). Conclusions A single dose of JE vaccine offered adequate protection for at least six years. Conducting mass vaccination campaigns periodically would further reduce the incidence of JE in endemic districts in Assam.